Serum level of endogenous secretory receptor for advanced glycation end products and other factors in type 2 diabetic patients with mild cognitive impairment

Diabetes Care

Volumn 34, Issue 12, 2011, Pages 2586-2590

  Chen, Gang ^a   Cai, Liangchun ^a   Chen, Bin ^a   Liang, Jixing ^a   Lin, Fenhui ^a   Li, Liantao ^a   Lin, Lixiang ^a   Yao, Jin ^a   Wen, Junping ^a   Huang, Huibin ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADVANCED GLYCATION END PRODUCT; ALPHA GLUCOSIDASE INHIBITOR; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE; C REACTIVE PROTEIN; CHOLESTEROL; DIURETIC AGENT; HEMOGLOBIN A1C; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; REPAGLINIDE; SULFONYLUREA; TRIACYLGLYCEROL; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR;

ADULT; ANKLE BRACHIAL INDEX; ARTERIAL WALL THICKNESS; ARTICLE; CHOLESTEROL BLOOD LEVEL; COGNITION; COGNITIVE DEFECT; COLOR ULTRASOUND FLOWMETRY; CONTROLLED STUDY; DISEASE DURATION; DYSLIPIDEMIA; ENDOCRINOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PULSE WAVE; SCORING SYSTEM; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT;

AGED; ANKLE BRACHIAL INDEX; CAROTID INTIMA-MEDIA THICKNESS; DIABETES MELLITUS, TYPE 2; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; RECEPTORS, IMMUNOLOGIC;

EID: 84860859435     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-0958     Document Type: Article

References (35)

1. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1133-1142
2. Petersen RC, Roberts RO, Knopman DS, et al.Mild cognitive impairment: ten years later. Arch Neurol 2009;66:1447-1455
3. Huebschmann AG, Regensteiner JG, Vlassara H, Reusch JE. Diabetes and advanced glycoxidation end products. Diabetes Care 2006;29:1420-1432 (Pubitemid 44125953)
4. Schmidt AM, Sahagan B, Nelson RB, Selmer J, Rothlein R, Bell JM. The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer's disease. Curr Opin Investig Drugs 2009;10:672-680
5. Santilli F, Vazzana N, Bucciarelli LG, DavìG. Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Curr Med Chem 2009;16:940-952
6. Yan SF, Ramasamy R, Schmidt AM. Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol 2010;79:1379-1386
7. Portet F, Ousset PJ, Visser PJ, et al.; MCI Working Group of the European Consortium on Alzheimer's Disease (EADC). Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease. J Neurol Neurosurg Psychiatry 2006;77:714-718 (Pubitemid 43837193)
8. Biessels GJ, van der Heide LP, Kamal A, Bleys RL, Gispen WH. Ageing and diabetes: implications for brain function. Eur J Pharmacol 2002;441:1-14 (Pubitemid 34465684)
9. Korf ES,White LR, Scheltens P, Launer LJ. Brain aging in very old men with type 2 diabetes: the Honolulu-Asia Aging Study. Diabetes Care 2006;29:2268-2274 (Pubitemid 44899864)
10. Gregg EW, Yaffe K, Cauley JA, et al. Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group. Arch Intern Med 2000;160:174-180 (Pubitemid 30054336)
11. Logroscino G, Kang JH, Grodstein F. Prospective study of type 2 diabetes and cognitive decline in women aged 70-81 years. BMJ 2004;328:548
12. Velayudhan L, Poppe M, Archer N, Proitsi P, Brown RG, Lovestone S. Risk of developing dementia in people with diabetes and mild cognitive impairment. Br J Psychiatry 2010;196:36-40
13. Roberts RO, Geda YE, Knopman DS, et al. Association of duration and severity of diabetes mellitus with mild cognitive impairment. Arch Neurol 2008;65:1066-1073
14. Fan WX, Parker R, Parpia B, et al. Erythrocyte fatty acids, plasma lipids, and cardiovascular disease in rural China. Am J Clin Nutr 1990;52:1027-1036 (Pubitemid 120008207)
15. Ryan CM, Geckle M. Why is learning and memory dysfunction in Type 2 diabetes limited to older adults? Diabetes Metab Res Rev 2000;16:308-315
16. Pavlović DM, Pavlović AM. Dementia and diabetes mellitus. Srp Arh Celok Lek 2008;136:170-175 [in Serbian]
17. Panza F, Frisardi V, Seripa D, et al. Metabolic syndrome, mild cognitive impairment, and dementia. Curr Alzheimer Res 2011;8:492-509
18. S Roriz-Filho J, Sá-Roriz TM, Rosset I, et al. (Pre)diabetes, brain aging, and cognition. Biochim Biophys Acta 2009;1792:432-443
19. Young SE,Mainous AG3rd, Carnemolla M. Hyperinsulinemia and cognitive decline in a middle-aged cohort. Diabetes Care 2006;29:2688-2693 (Pubitemid 44912200)
20. Rafnsson SB, Deary IJ, Fowkes FG. Peripheral arterial disease and cognitive function. Vasc Med 2009;14:51-61
21. Hanon O, Haulon S, Lenoir H, et al. Relationship between arterial stiffness and cognitive function in elderly subjects with complaints of memory loss. Stroke 2005;36:2193-2197 (Pubitemid 41429244)
22. Xu G, Zhou Z, Zhu W, Fan X, Liu X. Plasma C-reactive protein is related to cognitive deterioration and dementia in patients with mild cognitive impairment. J Neurol Sci 2009;284:77-80
23. Blasko I, Grubeck-Loebenstein B. Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer's disease. Drugs Aging 2003;20:101-113 (Pubitemid 36246292)
24. Petersen RC, Negash S. Mild cognitive impairment: an overview. CNS Spectr 2008;13:45-53 (Pubitemid 351224282)
25. Lue LF, Yan SD, Stern DM, Walker DG. Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease. Curr Drug Targets CNS Neurol Disord 2005;4:249-266 (Pubitemid 40754161)
26. Nozaki I,Watanabe T, Kawaguchi M, et al. Reduced expression of endogenous secretory receptor for advanced glycation endproducts in hippocampal neurons of Alzheimer's disease brains. Arch Histol Cytol 2007;70:279-290 (Pubitemid 351594919)
27. Emanuele E, D'Angelo A, Tomaino C, et al. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol 2005;62:1734-1736 (Pubitemid 41626671)
28. Ghidoni R, Benussi L, Glionna M, et al. Decreased plasma levels of soluble receptor for advanced glycation end products in mild cognitive impairment. J Neural Transm 2008;115:1047-1050
29. Koyama H, Shoji T, Yokoyama H, et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005;25:2587-2593 (Pubitemid 43732283)
30. Santilli F, Bucciarelli L, Noto D, et al. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic Biol Med 2007;43:1255-1262 (Pubitemid 47429934)
31. Lindsey JB, de Lemos JA, Cipollone F, et al. Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study. Diabetes Care 2009;32:1218-1220
32. Colhoun HM, Betteridge DJ, Durrington P, et al. Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial. Diabetes 2011;60:2379-2385
33. Semba RD, Ferrucci L, Sun K, et al. Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older communitydwelling women. Aging Clin Exp Res 2009;21:182-190
34. McNair ED, Wells CR, Mabood Qureshi A, et al. Modulation of high sensitivity C-reactive protein by soluble receptor for advanced glycation end products. Mol Cell Biochem 2010;341:135-138
35. An XF, Zhao Y, Yu JY, Liu JS, Gu WJ, Gao F. Plasma sRAGE is independently associated with high sensitivity C-reactive protein in type 2 diabetes without coronary artery disease. Diabetes Res Clin Pract 2010;87:e19-e22